2023-D-ESNCT06014775
Anti-CD38 Antibody Treating Evans Syndrome
StatusUnknown
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor Start date changed from estimate of Dec 2023 to Dec 1, 2023v3
- Notable Start date: Sep 2023 to Dec 2023v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Evaluation of overall efficacy response after Anti-CD38 antibody treatment within 8 weeks
Timeframe: 8 weeks
Safety of Anti-CD38 antibody treatment
Timeframe: 24 weeks
Secondary (15)
Evaluation of stable sustained response after Anti-CD38 antibody treatment at week 8
Number of Participants With ES Response to Anti-CD38 antibody treatment
Measurements of platelet count at each visit time point
Measurements of Hb value at each visit time point
Measurements of hemolytic marker reticulocyte count at each visit time point
Show 10 moreShow less
Measurements of hemolytic marker LDH at each visit time point
Measurements of hemolytic marker haptoglobin at each visit time point
Measurements of hemolytic marker total bilirubin at each visit time point
Emergency treatment
Duration of platelet response
Duration of Hb response
Reduction of concomitant drug
Number of subjects with clinically significant bleeding as assessed using the world health organization (WHO) bleeding scale
Assessment of fatigue function in chronic disease treatment
Health status survey
Arms and interventions
Intervention(Anti-CD38 antibody)Experimental
10 enrolled subjects : once a week x 8 doses
Drugs: Anti-CD38 antibody Injection
Sites
1 site in 1 country
- Chinese Academy of Medical Science and Blood Disease HospitalTianjin, Tianjin Municipality, China